Arcadia Biosciences
RKDA
27 hedge funds and large institutions have $7.4M invested in Arcadia Biosciences in 2021 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 9 increasing their positions, 4 reducing their positions, and 6 closing their positions.
303% more capital inflows, than outflows
Capital inflows: $4.86M | Capital outflows: $1.21M
125% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 4
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
17% more funds holding
Funds holding: 23 → 27 (+4)
6.29% more ownership
Funds ownership: 5.4% → 11.68% (+6.3%)
51% less call options, than puts
Call options by funds: $1.33M | Put options by funds: $2.74M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ardsley Advisory Partners
Stamford,
Connecticut
|
+$2.73M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.12M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$204K |
| 4 |
MYDA Advisors
Woodmere,
New York
|
+$123K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$104K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$370K |
| 2 |
Millennium Management
New York
|
-$245K |
| 3 |
Moloney Securities Asset Management
Manchester,
Missouri
|
-$198K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$183K |
| 5 |
BCM
Bayesian Capital Management
Brooklyn,
New York
|
-$99K |
RKDA Hedge Fund Activity: Q2 2021 in Review
27 of the 5,769 institutional investors tracked by Wall St. Rank reported a position in Arcadia Biosciences (RKDA) for Q2 2021, worth a combined $7.4M — up 134% from $3.17M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new RKDA positions and 6 closed out — a net gain of 4 holders — while 9 added to existing stakes and 4 trimmed.
The largest buyer was Ardsley Advisory Partners, opening a new position worth an estimated $2.73M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $370K sold.
- 27 institutional investors held Arcadia Biosciences (RKDA) as of Q2 2021, up from 23 in Q1 2021.
- Funds reported $7.4M of Arcadia Biosciences stock for Q2 2021, up 134% quarter-over-quarter.
- 10 funds opened new Arcadia Biosciences positions in Q2 2021 and 6 closed out, a net change of +4 holders.
- The largest Arcadia Biosciences buyer in Q2 2021 was Ardsley Advisory Partners, an estimated $2.73M added.
- The largest Arcadia Biosciences seller in Q2 2021 was Susquehanna International Group, an estimated $370K sold.
Based on aggregated 13F filings for Q2 2021.